New Stock Listings - New stock "能之光" (Code: 920056) listed at an issue price of 7.21 on August 22, 2025[1] - "申科股份" (Code: 002633) has a tender offer period from July 29 to August 27, 2025[1] - "抚顺特钢" (Code: 600399) has a tender offer period from August 12 to September 10, 2025[1] Abnormal Fluctuations - "赛诺医疗" (Code: 688108) reported severe abnormal fluctuations on August 19, 2025[1] - "ST苏吴" (Code: 600200) announced abnormal fluctuations on August 21, 2025[1] - "汇嘉时代" (Code: 603101) reported abnormal fluctuations on August 22, 2025[1] Other Notable Announcements - "酒鬼酒" (Code: 000799) reported an announcement on August 21, 2025[1] - "国机精工" (Code: 002046) had an announcement on August 21, 2025[1] - "全柴动力" (Code: 600218) reported an announcement on August 21, 2025[1]

证券代码：600200 证券简称：*ST苏吴 公告编号：临2025-090 江苏吴中医药发展股份有限公司 关于股票交易暨退市风险提示公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要风险提示： 二、公司存在财务类退市风险 公司 2024 年度财务报告被年审机构出具无法表示意见，触及《上海证券交 易所股票上市规则》第 9.3.2 条第（三）项规定财务类退市的情形，公司股票已 被上海证券交易所实施退市风险警示。具体内容详见公司于 2025 年 4 月 30 日披 露的《关于实施退市风险警示及叠加其他风险警示暨停牌的公告》（公告编号： 临 2025-032）。 三、叠加实施其他风险警示 公司 2024 年度财务报告内部控制被年审机构出具无法表示意见；浙江复基 控股集团有限公司的其他关联方企业存在非经营性占用公司资金的情形。上述事 项触及《上海证券交易所股票上市规则》第 9.8.1 条第（一）（三）项的规定， 公司被叠加实施其他风险警示。具体内容详见公司于 2025 年 5 月 6 日披露的《关 于控股股东关联方资金占用暨叠加 ...

Group 1 - The average stock price of A-shares is 13.27 yuan, with 33 stocks priced below 2 yuan, the lowest being *ST Suwu at 1.01 yuan [1] - Among the low-priced stocks, 13 are ST stocks, accounting for 39.39% of the total [1] - The Shanghai Composite Index closed at 3825.76 points as of August 22 [1] Group 2 - The top gainers among low-priced stocks include *ST Suwu, Jinju Group, and *ST Xingguang, with increases of 5.21%, 1.82%, and 1.55% respectively [1] - The top decliners include *ST Gaohong, *ST Jinke, and Jiugang Hongxing, with decreases of 5.00%, 1.46%, and 1.14% respectively [1] - The trading volume and turnover rates vary significantly among low-priced stocks, with *ST Suwu having a turnover rate of 3.49% [1]

Group 1 - The article discusses the monitoring periods for various stocks, indicating specific start and end dates for monitoring activities [1] - Notable companies mentioned include *ST Suwu, Sainuo Medical, Dongxin Co., and Changcheng Military Industry, with specific dates for monitoring and abnormal activity [1] - Sainuo Medical appears multiple times with different monitoring periods, suggesting increased scrutiny or volatility [1] Group 2 - The monitoring periods for Sainuo Medical are from August 14, 2025, to August 27, 2025, with abnormal activity starting on August 7, 2025 [1] - Dongxin Co. has a monitoring period from August 18, 2025, to August 29, 2025, with abnormal activity starting on July 7, 2025 [1] - Changcheng Military Industry's monitoring period is from August 14, 2025, to August 27, 2025, with abnormal activity starting on July 31, 2025 [1]

Group 1 - The company announced the resignation of Vice President and Chief Financial Officer Sun Xi due to work adjustments, effective from August 21, 2025 [2] - The board approved the proposal for the company's President Jiang Zhong to temporarily assume the duties of the Chief Financial Officer until a new appointment is made [2] - The company will promptly hire a new Chief Financial Officer and fulfill related disclosure obligations as per legal requirements [2] Group 2 - The company is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, leading to a risk warning for potential delisting due to major violations [5][6] - The company received a notice from the CSRC on July 13, 2025, indicating that it had inflated revenue, costs, and profits in its annual reports from 2020 to 2023, with inflated revenues amounting to approximately 495.26 million yuan in 2020, 468.51 million yuan in 2021, 430.75 million yuan in 2022, and 376.66 million yuan in 2023 [7] - The company's stock price has been below 1 yuan for six consecutive trading days, which could lead to termination of listing if it remains below this threshold for 20 consecutive trading days [5][6]

Core Viewpoint - The company, Jiangsu Wuzhong Pharmaceutical Development Co., Ltd., is facing the risk of being delisted due to significant legal violations, as it has been under investigation by the China Securities Regulatory Commission (CSRC) for falsifying financial statements from 2020 to 2023 [1][2][3] Group 1: Investigation and Legal Proceedings - The company received a notice of investigation from the CSRC on February 26, 2025, regarding its subsidiaries' involvement in non-substantive trade activities that inflated revenue, costs, and profits [1][2] - The CSRC's preliminary findings indicate that the company inflated its reported revenue by 26.46%, 26.39%, 21.26%, and 16.82% for the years 2020 to 2023, respectively [1] - The inflated operating costs amounted to 480.68 million yuan, 448.24 million yuan, 410.82 million yuan, and 355.44 million yuan for the same years, representing 37.08%, 35.47%, 28.40%, and 20.95% of the reported costs [1] Group 2: Stock Performance and Risks - The company's stock has been under a warning for potential delisting since July 14, 2025, due to the ongoing investigation and the risk of significant legal violations [2] - The stock price has been below 1 yuan for six consecutive trading days, which could lead to termination of listing if it remains below this threshold for 20 consecutive trading days [2] - The company has experienced significant stock price volatility, and there are concerns about speculative trading, urging investors to make informed decisions [2][3]

证券代码：600200 证券简称：*ST 苏吴 公告编号：临 2025-089 江苏吴中医药发展股份有限公司关于公司股票 可能被实施重大违法强制退市的第七次风险提示公告 本公司董事会及董事会全体成员保证公告内容不存在虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实、准确和完整承担法律责任。 2025 年 7 月 13 日，公司收到中国证监会下发的《行政处罚事先告知书》（处 罚字〔2025〕58 号），认定公司子公司江苏吴中进出口有限公司、中吴贸易发 展(杭州)有限公司、江苏吴中海利国际贸易有限公司通过与浙江优诺德贸易有限 公司等多家关联公司开展无商业实质的贸易业务，虚增营业收入、营业成本和利 润。上述行为导致*ST 苏吴在 2020 年至 2023 年年度报告中分别虚增营业收入 49,526.32 万元、46,850.82 万元、43,074.52 万元、37,666.41 万元，占当期披 露营业收入的 26.46%、26.39%、21.26%、16.82%；分别虚增营业成本 48,068.05 万元、44,823.70 万元、41,082.09 万元、35,544.47 万元，占当期披露营业成 本的 3 ...

关于副总裁、财务总监辞职暨总裁代行财务总监职责的公告 证券代码：600200 证券简称：*ST 苏吴 公告编号：临 2025-088 江苏吴中医药发展股份有限公司 本公司董事会及董事会全体成员保证公告内容不存在虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实、准确和完整承担法律责任。 二、关于总裁代行财务总监职责的情况 江苏吴中医药发展股份有限公司 董事会 2025 年 8 月 22 日 一、副总裁、财务总监离任情况 姓名 离任职务 离任时间 原定任期到 期日 离任原因 是否继续在上市 公司及其控股子 公司任职 具体职务 （如适用） 是否存在未 履行完毕的 公开承诺 孙曦 副总裁、财 务总监 2025 年 8 月 21 日 2027 年 3 月 22 日 工作调整 原因 是 不适用 不适用 江苏吴中医药发展股份有限公司（以下简称"公司"）董事会于 2025 年 8 月 21 日收到孙曦先生的书面辞职报告，因工作调整原因，孙曦先生辞去公司副 总裁、财务总监职务，辞职后公司将另有任用。孙曦先生的辞职报告自送达董事 会之日起生效。 为保障公司财务管理工作的顺利开展，经公司董事会审计委员会同意，公司 于 2025 ...

New Stock Offerings - Shenke Co., Ltd. (002633) has a tender offer period from July 29, 2025, to August 27, 2025[1] - Fushun Special Steel (600399) has a tender offer period from August 12, 2025, to September 10, 2025[1] - Changcheng Military Industry (601606) announced a significant event on August 14, 2025[1] Market Alerts - Dongxin Co., Ltd. (688110) reported severe abnormal fluctuations on August 16, 2025[1] - ST Suwu (600200) has an announcement dated August 21, 2025, regarding market conditions[1] - Yunnan Zhiye (002428) and other companies have recent announcements on August 21, 2025, indicating market activity[1] Financial Performance - ST Jiangsu (600021) reported significant fluctuations on August 20, 2025, with a notable announcement[1] - ST Huanrong (600421) has an announcement dated August 20, 2025, reflecting market conditions[1] - ST Jinhong (000669) reported on August 20, 2025, indicating financial performance concerns[1]

证券之星消息，8月21日化学制药板块较上一交易日上涨0.09%，*ST苏吴领涨。当日上证指数报收于 3771.1，上涨0.13%。深证成指报收于11919.76，下跌0.06%。化学制药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 600200 | *ST苏吴 | 0.96 | 5.49% | 43.67万 | | 4141.60万 | | 300705 | 九典制药 | 19.87 | 4.97% | 52.35万 | | 10.35 Z | | 300573 | 兴齐眼药 | 67.48 | 4.69% | 22.77万 | | 15.19 Z | | 688506 | 百利天恒 | 324.96 | 4.21% | 1.62万 | | 5.23亿 | | 002940 | 昂利康 | 51.36 | 3.86% | 15.16万 | | 7.69亿 | | 002020 | 京新药业 | 19.52 | 2.90% | 32.05万 | | 6.16 ...